All blog posts
Total 23 results for
Showing 12 out of 23 results
01 November 2024
EU Commission fines Teva €462.6 million for misuse of divisional patents and disparagement campaign
14 October 2024
Highlights from the GCR Live: Competition Litigation conference
07 October 2024
General Court largely rejects Qualcomm's challenge to Commission's predatory pricing decision
21 December 2023
Clarity: Over the Hills and (F)Far Away? The FIFA Football Agents Regulations and their interplay with competition law
06 December 2023
Competition law and biosimilars: Time for a new approach or not yet?
15 June 2023
Overview of EU and South African regulatory and competition law in the Pharma sector
14 April 2023
European Commission announces plans for new Article 102 TFEU Guidelines and amends 2008 Guidance on enforcement priorities
24 March 2023
Non-notifiable M&A deals can be reviewed under abuse of dominance rules: does heightened regulatory intervention in deal-making lie ahead?
23 November 2022
SANCTION IMPOSED BY THE SPANISH COMPETITION AUTHORITY ON A PHARMA COMPANY FOR MISUSING LITIGATION STRATEGIES REGARDING PATENTS
11 October 2022
Update on the Teva Copaxone EU case. The EU Commission issues a Statement of Objections against Teva over alleged anti-competitive conduct consisting of misuse of divisional patents and a disparagement campaign against its closest competitor
27 June 2022
Overview of EU and South African regulatory and competition law in the Pharma sector
04 March 2021
First time EU Commission pursues case relating to divisional patent filing and litigation strategies
Showing 12 out of 23 results
View moreKey contacts
Kyriakos Fountoukakos
Managing Partner, Competition Regulation and Trade, Brussels
Veronica Roberts
Partner, UK Regional Head of Practice, Competition, Regulation and Trade, London
Linda Evans
Regional Head of Practice – Competition, Regulation and Trade, Australia, Sydney
